|
License
to copy
Is the Indian pharmaceutical industry developing generics
at the cost of innovation? Arshiya Khan does a status check
GVK
BIO joins hands with Wyeth
GVK BIO has entered into a research agreement with Wyeth Pharmaceuticals,
to discover drug candidates focused on pre-defined discovery
targets.
GSK
in agreement with Daiichi Sankyo
GlaxoSmithKline (GSK) has signed a co-promotion agreement
with Daiichi Sankyo India Pharma for anti-hypertensive drug
Olmesartan Medoxomil and its combination products.
Arch
Pharmalabs signs MoU with Texcell SA
Arch Pharmalabs announced that it will represent Texcell SA,
a world-renowned service company based in France providing
viral safety and immunology services in India.
Anu's
Laboratories announces IPO
Anu's Laboratories engaged in the manufacture of basic, advanced
intermediates and fine chemicals entered the capital markets
on May 12 2008 with a public issue of 38,20,000, equity shares
of Rs 10 each including employees reservation portions of
2 lakh equity shares through 100 percent book building process
in the price band of Rs 200 to Rs 210 per equity share.
GSK
inaugurates its technical development centre in Nashik
GlaxoSmithKline (GSK) launched its technical development centre
in India. This is GSK's new state of art technical development
centre in India.
Veeda
Oncology acquires B&I
Veeda Oncology has completed the acquisition of Biologie et
Industrie (B&I), based in Paris, France.
Suven
gets two product patents
Suven Life Sciences has been granted with two product patents
in South Africa and China for two of their new chemical entities
(NCEs) for the treatment of disorders associated with neuro-degenerative
diseases.
CREMA
join hands with Clinical Research International
CREMA (Clinical Research Education and Management Academy),
has formed a joint venture with Canada-based Clinical Research
International, by which students can enroll for online certification
courses.
Novartis
India supports world hepatitis alliance initiative
Novartis in India supports the initiative taken by the newly
formed non-governmental organisation, the World Hepatitis
Alliance, to call on governments around the world to do more
to drive improvements in prevention, diagnosis and treatment
for people living with chronic viral hepatitis B and C.
Trivitron
to invest Rs 170 crore for technology park
Trivitron group of companies has laid the foundation stone
for construction of Trivitron's Medical Technology Park (TMTP)
at the SIPCOT industrial park, Irungattukottai, Sriperambadur.
ABTL
join hands with Huvepharma
Advance Bio Agro Tech Limited (ABTL) has entered into a marketing
and manufacturing agreement with Huvepharma.
Merck
Sharp and Dohme launches DPP-4 inhibitor in India
Merck Sharp and Dohme (MSD) Pharmaceuticals, the wholly owned
subsidiary of Merck, recently launched its once daily, type
II diabetes tablet, Januvia (sitagliptin) in India.
IBPL
to market Gefitinib in India
Intas Biopharmaceuticals Limited (IBPL) is to market lung
cancer drug, gefitinib, under brand name 'Geffy', in the Indian
market.
Macred
India to divest 49 percent to Johnson Matthey
Dr Reddy's Laboratories will divest 49 percent stake in its
wholly-owned subsidiary Macred India to Johnson Matthey, a
$4.2-billion British drug major, for technology that derives
controlled substances such as morphine, codeine, dionine and
thebaine from opium.
Events
60th
IPC to be held in New Delhi
At the outset of deciding the minutes of the meeting of the
Local Organising Committee (LOC), of 60th IPC 2008, held on
7th April, it was also declared that the 60th Indian Pharmaceutical
Congress (IPC) will be held in New Delhi from 12th to 14th
December, 2008, at Netaji Subash Institute of Technology.
HbA1c—effective
way of controlling diabetes
Tests like HbA1c help diabetes patients to control their plasma
sugar levels more effectively. Suja Nair gets more
details at a recently held Bio Rad Laboratories seminar
Quality
speaks
IDMA's seminar showcased the importance of quality and how
there is no alternative for quality, as it is the driving
force behind any industry, especially pharma. Suja Nair and
Manjusha Morgaonkar reports
|
